VERTEX PHARMACEUTICALS INC / MA Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$30.50 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was -$30.50M.
- VERTEX PHARMACEUTICALS INC / MA valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was -$178.20M, a 1304.05% decline from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $14.80M, a 95.17% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $306.40M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2019-12-31 | -$30.50M 10-K · filed 2020-02-13 |
| 2017-12-31 | -$178.20M 10-K · filed 2019-02-13 |
| 2016-12-31 | $14.80M 10-K · filed 2019-02-13 |
| 2015-12-31 | $306.40M 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |